This is considered standard, testing of the product and business strategies Targanta Therapeutics, a biotechnology company preparing its first new drug application FDA. In October 2007, Mark Leuchtenberger, President and Chief Executive Officer of Targanta - which just concluded a successful IPO - weighs options for about ten month review period after the company represents the Food and Drug Administration. The case considers the origin Targanta and "de-risk" of oritavancin, antibiotic drug-resistant infections, which was first invented at Eli Lilly, and then turned to InterMune to Targanta acquired it in late 2005. In order to isolate the impact of regulatory policy on business strategy so that describes a set of options facing the company, including sales and marketing personnel groups, conduct additional clinical trials to expand approved indications applying in the European market approval or deposited funds in reserve case, FDA asks for more data. "Hide
by Arthur A. Daemmrich Source: Harvard Business School 24 pages. Publication Date: January 13, 2009. Prod. #: 709002-PDF-ENG
Related Case Solutions & Analyses:
Kansai Digital Phone: Zutto Gaining Japanese Loyalty
Coffee Wars in India: Cafe Coffee Day Takes on the Global Brands
Himalaya Shampoo: Building a Differentiated Brand Image
Marketing Plan Development
Tata Nano: The People’s Car that Promises to Reconstruct the Automobile Industry
Coursera
Breakfast Club
Marketing Plan – Focus Glasses
Xanadu on Broadway
HP: The Computer is Personal Again
